Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
CQU | Ann: Change in substantial holding | 16/11/09 | 0 | 997 | |||
|
|||||||
CQU | Ann: Ceasing to be a substantial holder | 13/11/09 | 0 | 933 | |||
|
|||||||
CQU | Ann: Change in substantial holding | 13/11/09 | 0 | 956 | |||
|
|||||||
CQU | Ann: Change in substantial holding | 13/11/09 | 0 | 928 | |||
|
|||||||
CQU | Ann: Becoming a substantial holder | 13/11/09 | 0 | 954 | |||
|
|||||||
CQU | Ann: Change of Director's Interest Notice | 12/11/09 | 0 | 829 | |||
|
|||||||
CQU | Ann: Appendix 3B | 12/11/09 | 0 | 473 | |||
|
|||||||
CQU | Ann: Market Update | 11/11/09 | 0 | 478 | |||
|
See All Discussions